Please login to the form below

Not currently logged in
Email:
Password:

Cancer therapy

This page shows the latest Cancer therapy news and features for those working in and with pharma, biotech and healthcare.

AZ scores FDA priority review for new Imfinzi fixed-dose regimen

AZ scores FDA priority review for new Imfinzi fixed-dose regimen

This includes unresectable, stage three non-small cell lung cancer (NSCLC) after chemoradiation therapy and previously-treated advanced bladder cancer. ... Last year, Imfinzi added almost $1.5bn to AZ’s top-line, mainly due to the drug's use as a

Latest news

  • AstraZeneca’s Imfinzi fails first-line bladder cancer test AstraZeneca’s Imfinzi fails first-line bladder cancer test

    cancer that has spread to other parts of the body compared to standard chemotherapy. ... It also delays further competition to Roche’s rival PD-L1 inhibitor Tecentriq (atezolizumab), which became the first checkpoint inhibitor to be approved for

  • Keytruda hits primary endpoint in confirmatory lymphoma trial Keytruda hits primary endpoint in confirmatory lymphoma trial

    It was the first green light for the drug in a haematological cancer, and Keytruda has since gone on to receive approval in primary mediastinal B-cell lymphoma, a rare form ... Keytruda’s main growth indication is undoubtedly non-small cell lung cancer,

  • Boehringer links up with Trutino for cancer R&D Boehringer links up with Trutino for cancer R&D

    That includes the takeover of oncolytic virus specialist ViraTherapeutics at the end of 2018, which is focused on the latter’s lead candidate VSV-GP, a cancer therapy that works by ... The Lupin deal came only a few short weeks after Boehringer

  • Celgene’s Revlimid scores NICE approval in follicular lymphoma Celgene’s Revlimid scores NICE approval in follicular lymphoma

    Lenalidomide is a new type of targeted cancer therapy for people with previously treated follicular lymphoma. ... Revlimid is already approved for use in a host of additional blood cancer indications – most notably multiple myeloma, where it is

  • IMV preps pivotal trials for ovarian cancer T cell therapy IMV preps pivotal trials for ovarian cancer T cell therapy

    The Canadian biotech revealed data from the 22-patient DeCidE1 study shows that the drug stabilised disease in 79% of 19 evaluable patients with advanced, recurrent ovarian cancer, with more than ... It said the results were impressive given that the

More from news
Approximately 1 fully matching, plus 464 partially matching documents found.

Latest Intelligence

  • Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy

    Selumetinib was given ‘breakthrough therapy’ status and rapidly green-lit by the FDA last month (April) following a promising National Cancer Institute (NCI) Cancer Therapy Evaluation Program sponsored phase 2 trial. ... targets of small cell lung

  • China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

    There was no robust, regulatory control but that has changed and any cell therapy now has to be properly approved.”. ... Tightening up regulatory policies was vital in order to move on from the cell therapy lowlight that saw a 21-year-old student die

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    and Braftovi) that Pfizer thinks could become a top industry franchise in colorectal cancer when combined with antibody drug cetuximab. ... to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... The HER2-targeting antibody-drug conjugate (ADC) combines the HER2-targeting of Roche’s blockbuster breast cancer

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    Diefenbach said: “The promise of being able to tailor cancer therapy to biology and risk is at the forefront of the drive to discover novel biomarkers. ... The idea of cancer biomarkers is to find one that exists to the exclusion or near-exclusion of

More from intelligence
Approximately 0 fully matching, plus 22 partially matching documents found.

Latest appointments

  • New hires at Ferring, Flexion and Immunocore New hires at Ferring, Flexion and Immunocore

    It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell

  • Dr Li Zhou joins TxCell as cell engineering VP Dr Li Zhou joins TxCell as cell engineering VP

    transplantation. He joins from ZMKS International Cancer Therapy Biotechnologies, a Chinese immuno-oncology company, where he served as chief scientific officer and director of research and development.

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice

  • Merck appoints ex-Pfizer exec as global head of oncology Merck appoints ex-Pfizer exec as global head of oncology

    lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer.

  • Kiadis Pharma appoints Vincent Brichard to supervisory board Kiadis Pharma appoints Vincent Brichard to supervisory board

    protect us from infectious diseases – to recognise and kill cancer cells. . ... Atir achieved some extremely compelling clinical data and the phase II study interim analysis in December demonstrated the drug's true potential as an adjunctive

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Employee engagement
Route 66: can remote working put two-thirds of us back on the road to engaged employment?
Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...

Infographics